Revolution Medicines Inc - Asset Resilience Ratio
Revolution Medicines Inc (RVMD) has an Asset Resilience Ratio of 76.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Revolution Medicines Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Revolution Medicines Inc's Asset Resilience Ratio has changed over time. See Revolution Medicines Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Revolution Medicines Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RVMD company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.71 Billion | 76.12% |
| Total Liquid Assets | $1.71 Billion | 76.12% |
Asset Resilience Insights
- Very High Liquidity: Revolution Medicines Inc maintains exceptional liquid asset reserves at 76.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Revolution Medicines Inc Industry Peers by Asset Resilience Ratio
Compare Revolution Medicines Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Revolution Medicines Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Revolution Medicines Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 68.26% | $1.75 Billion | $2.56 Billion | +12.15pp |
| 2023-12-31 | 56.11% | $1.16 Billion | $2.06 Billion | -3.44pp |
| 2022-12-31 | 59.55% | $483.53 Million | $811.93 Million | -3.94pp |
| 2021-12-31 | 63.49% | $468.56 Million | $737.99 Million | +4.19pp |
| 2020-12-31 | 59.30% | $336.47 Million | $567.40 Million | +11.19pp |
| 2019-12-31 | 48.11% | $106.10 Million | $220.53 Million | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more